Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease

  1. Regina Kunz, MD, MSc(Epi);
  2. Chris Friedrich, MD;
  3. Marcel Wolbers, PhD; and
  4. Johannes F.E. Mann, MD
  1. From Basel Institute for Clinical Epidemiology and Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland, and Munich General Hospitals, Ludwig Maximilian University, Munich, Germany.
    1. Appendix Figure 1.
      View larger version:
      Appendix Figure 1. Study flow diagram.Graphic
    2. Appendix Figure 2.
      View larger version:
      Appendix Figure 2. Quality assessment.

      ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; CCB = calcium-channel blocker; Combi = combination therapy.

    3. Figure 1.
      View larger version:
      Figure 1. Reduction in proteinuria at 1 to 4 months.

      ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker.

    4. Figure 2.
      View larger version:
      Figure 2. Reduction in proteinuria at 5 to 12 months.

      ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker.

    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med January 1, 2008 vol. 148 no. 1 30-48
    1. AbstractFREE
    2. » Figures
    3. Full Text
    4. Full Text (PDF)
    5. Audio Summary

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues